Investigational drug · Phase 2
SYT-510
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Generalized Anxiety Disorder.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SYT-510"
First trial start
2026
Apr 22, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYT-510", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Anxiety Disorder
Approved drugs for the same conditions: Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "SYT-510" as an intervention, largest first.
Synendos Therapeutics AGIndustry
NCT06670950 · 28 participants · Start Nov 4, 2024 · Primary completion May 17, 2025
Drug: SYT-510; SYT-510 and 2 more · For: Healthy
Sites: London, United Kingdom
Synendos Therapeutics AGIndustry
NCT07478744 · 24 participants (planned) · Start Apr 22, 2026 · Primary completion Jan 2027
Drug: SYT-510; Placebo · For: Generalized Anxiety Disorder
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Generalized Anxiety Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- BuagafuranPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Buagafuran mimicPhase 32 trials
Beijing Union Pharmaceutical Factory Ltd · Generalized Anxiety Disorder
- Toludesvenlafaxine Hydrochloride Sustained-releasePhase 31 trial
Luye Pharma Group Ltd. · Generalized Anxiety Disorder
- ENX-102ENX-102 -dose, ENX-102 mid-dosePhase 23 trials
Engrail Therapeutics INC · General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder
- RE104Phase 23 trials
Reunion Neuroscience Inc · Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.